Context Therapeutics Inc. (CNTX)

NCM – Real Time Price. Currency in USD

2.48

+0.09 (3.77%)

At close: May 12, 2026, 4:00 PM EDT

2.54

+0.06 (2.42%)

After-hours: May 12, 2026, 6:38 PM EDT

06.05.2026

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for CT-202 (Nectin-4 x CD3) trial expected in third quarter of 2026 Cash and cash equivalents of $54.5 million as of March 31, 2026 expected to fund operations into mid-2027 PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the first quarter ended March 31, 2026, and reported on recent and upcoming business highlights. “We continue to execute across our pipeline and believe we are making meaningful scientific and operational progress,” said Martin Lehr, Chief Executive Officer of Context Therapeutics.

02.04.2026

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer (“PROC”) in patients that have received all standard of care therapies. Context is currently evaluating CTIM-76 in a Phase 1 clinical trial designed to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers.

23.03.2026

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA, March 23, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights. “We believe 2025 was a year of significant progress for Context as we advanced our pipeline of T cell-engaging bispecific antibodies for solid tumors.

19.03.2026

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, CA. The presentation will highlight preclinical data regarding the Company's asset, CT-202, a Nectin-4 x CD3 TCE.

09.02.2026

Context Therapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its participation in several upcoming investor conferences.

16.01.2026

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context.

07.11.2025

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today shared two posters discussing the Company's CT-95 and CT-202 programs at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, being held November 7–9, 2025 in National Harbor, MD. CT-95 and CT-202 Highlights and Near-Term Milestones CT-95: Mesothelin x CD3 bispecific TCE CT-95 is avidity enhanced and affinity tuned to localize therapeutic activity to the tumor microenvironment.

Videos

No Data

There is no data to display

Press releases

06.05.2026

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

02.04.2026

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

23.03.2026

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

19.03.2026

Context Therapeutics Inc. (CNTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Context Therapeutics Inc. (CNTX)

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Context Therapeutics to Participate in Upcoming Investor Conferences

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Videos

No Data

Press releases

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Context Therapeutics to Participate in Upcoming Investor Conferences

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Videos

No Data

Press releases

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Search stocks

Context Therapeutics Inc. (CNTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Context Therapeutics Inc. (CNTX)

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Context Therapeutics to Participate in Upcoming Investor Conferences

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Videos

No Data

Press releases

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Context Therapeutics to Participate in Upcoming Investor Conferences

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Videos

No Data

Press releases

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026